换一批
换一批Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.
第一作者：
Fotios,Loupakis
第一单位：
UO Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
作者：
主题词
血管生成抑制剂(Angiogenesis Inhibitors);抗体, 单克隆(Antibodies, Monoclonal);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic);临床试验, Ⅲ期(主题)(Clinical Trials, Phase III as Topic);结直肠肿瘤(Colorectal Neoplasms);女(雌)性(Female);人类(Humans);男(雄)性(Male);随机对照试验(主题)(Randomized Controlled Trials as Topic);挽救疗法(Salvage Therapy);治疗结果(Treatment Outcome)
DOI
10.1186/1756-9966-29-58
PMID
20504361
发布时间
2021-10-20
- 浏览14
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
